Zymogenetics, Inc.

University of Washington

Catherine E Lofton-Day

Si Lok

Darrell C Conklin

Stephen R Jaspers

Robyn L Adams

Anna C Jelmberg

Michael R Stamm

John J Albers

Janet L Adolphson

Joseph R Day

Scott R Presnell

Donald C Foster

Julia E Novak

Wenfeng Xu

Joseph Leon Kuijper

Richard D Holly

Yue Yao

Frederick S Hagen

Randal Henne

John W Forstrom

Kenneth Kaushansky

Pieter J Oort

Novel secreted and membrane bound tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate inflammation, tumor growth and metastasis, infection, immunity, and cellular maturation.

UMLR polypeptides

The present invention provides testis-specific insulin homolog polypeptides and polynucleotides encoding the polypeptides, as well as related compositions and methods are disclosed. The polypeptides and polynucleotides may be used within methods for enhancing viability of cryopreserved sperm, for enhancing sperm motility, to enhance fertilization in methods of assisted reproduction, as contraceptives and other related uses.

Antibodies that bind testis-specific insulin homolog polypeptides

Testis-specific insulin homolog polypeptides

The present invention relates to polynucleotides encoding for novel insulin homolog polypeptides that have been designated Zins3. The human and mouse polynucleotides and corresponding polypeptides are described, and comprise a B chain, A chain, and C-peptide, or portions thereof. The polynucleotide sequence maps to human chromosome 12.

Polynucleotides encoding insulin homolog zins3

Methods for stimulating granulocyte/macrophage lineage cells using thrombopoiet in are provided. The methods provided may be used to stimulate granulocyte/macrophage progenitors and neutrophils in bone marrow and peripheral blood cells and in vitro and in vivo. In addition, methods for treatment of neutropenia in patients are disclosed.

Methods for stimulating granulocyte/macrophage lineage using

Purified mammalian thrombopoietin proteins and methods of making them are disclosed. The proteins are characterized by a M.sub.r =70,000.+-.10,000 daltons as determined by SDS-polyacrylamide gel electrophoresis under denaturing conditions and are at least 90% pure with respect to contaminating proteins. The proteins can be prepared by a method in which thrombopoietin is adsorbed to and eluted from a polypeptide comprising a ligand-binding domain of an MPL receptor, then the eluted thrombopoietin is fractionated by anion exchange chromatography.

Purified thrombopoietin and method of making it

Isolated polynucleotide molecules encoding mammalian phospholipid transfer proteins (PLTP) and phospholipid transfer protein polypeptides are disclosed. The DNA molecules are transformed or transfected into host cells and the cells cultured to produce recombinant PLTP and PLTP polypeptides. PLTP and PLTP polypeptides may be combined with a pharmaceutically acceptable vehicle and administered to patients to regulate phospholipid transfer activity and thereby obtain a more favorable lipoprotein profile in the blood. The proteins and polypeptides may also be used within methods to measure phospholipid transfer activity or identify inhibitors of phospholipid transfer activity.

Phospholipid transfer proteins and DNA encoding them

Methods of detecting phospholipid transfer activity and kits therefor

Growing community of inventors

Brier, WA, United States of America

Catherine E Lofton-Day